05 2023.06

Expanded Access Policy for Investigational Product

01 2023.06

Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023

08 2023.05

[Other - Business Update] VOLUNTARY ANNOUNCEMENT - RC198 RECEIVED ETHICS APPROVAL FOR THE PHASE I CLINICAL TRIAL IN AUSTRALIA, AND THE COMPANY WILL INITIATE THE STUDY TO TREAT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMORS

05 2023.05

Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2023

27 2023.04

[Overseas Regulatory Announcement - Other] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

27 2023.04

[Overseas Regulatory Announcement - Corporate Governance Related Matters] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

27 2023.04

[Overseas Regulatory Announcement - Other] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

27 2023.04

[Overseas Regulatory Announcement - Other] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

27 2023.04

[Overseas Regulatory Announcement - Corporate Governance Related Matters] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

27 2023.04

[Inside Information / Quarterly Results / Overseas Regulatory Announcement - Trading Update] 2023 FIRST QUARTERLY REPORT